Compass Therapeutics Q2 net loss $25.2M; tovecimig ORR improves to 18.0% with p=0.0228

Compass Therapeutics, Inc.

Net loss of $25.2M ($0.13/sh) vs $19.9M ($0.14/sh) in Q2 2025; R&D spend rose 19% to $19.6M.
Cash and marketable securities $180M as of June 30, 2026; runway into 2028.
Tovecimig Phase 2/3 ORR improved to 18.0% (20/111) with p=0.0228 vs paclitaxel 5.3%.
FDA feedback on tovecimig data expected Q3 2026; BLA submission planned later this year.
CTX-8371 cohort expansions enrolling; CTX-10726 Phase 1 dosed; CTX-471 Phase 2 starts Q3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.